

An error appeared in the initial publication of this article [den Heijer CDJ, Hoebe CJPA, Driessen JHM, et al. Chlamydia trachomatis and the Risk of Pelvic Inflammatory Disease, Ectopic Pregnancy, and Female Infertility: A Retrospective Cohort Study Among Primary Care Patients. *Clin Infect Dis* <https://doi.org/10.1093/cid/ciz429>]. This article was originally published with the following error:

In the financial support section, it currently states the following:

“This study was supported by the Netherlands Organisation for Health Research and Development (ZonMW, registration number: 50–53,000–98–103).”

It should state:

“This study was supported by the Netherlands Organisation for Health Research and Development (ZonMW, project number: 522002013).”

The author regrets this error.

DOI: 10.1093/cid/ciz897

An error appeared in the “corrected proof” publication of this article [Merat S and the SD1000 Research Team. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. *Clin Infect Dis* <https://doi.org/10.1093/cid/ciz628>]. This article was published with the following error:

In the “Potential conflicts of interest” section, it currently states the following:

“S. M. is an employee of the Tehran University of Medical Sciences (TUMS); has received research grants from TUMS; has received travel grants from Rojan Pharma and Gilead Sciences; serves as consultant for and has received travel grants from Abbvie Pharmaceuticals; and is a stockholder of Rojan Pharma. The author has submitted the ICMJE Form for Disclosure of

Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.”

It should state the following:

“SM, HP, AHS, AAS, RJ, and RM are employees of TUMS. BF and ANB are employees of Rojan Pharma. SM and HP have received research grants from TUMS. SM and HP have received travel grants from Rojan Pharma. SM, HP, and AHS have received travel grants from Gilead Sciences. SM serves as consultant and has received travel grants from Abbvie pharmaceuticals. SM, AHS, ANB, and BF are stock holders of Rojan Pharma. HP and RM were stockholders of Rojan Pharma at the beginning of the study and they sold their stocks in 2019. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.”

The author regrets this error.

DOI: 10.1093/cid/ciz931

The following error appeared in the corrected proof publication of this article [Bradbury RS, Travers-Gustafson D, Sapp SGH, et al. A Second Case of Human Conjunctival Infestation With *Thelazia gulosa* and a Review of *T. gulosa* in North America. *Clin Infect Dis* <https://doi.org/10.1093/cid/ciz469>].

In the fourth paragraph of the Case Report section, it currently states “The formalin-preserved nematode sample collected in Monterrey was sent to the California State Public Health laboratory, where it was identified morphologically as *Thelazia* spp. The sample was then forwarded to the Centers for Disease Control

and Prevention (CDC) Parasitic Diseases Reference Laboratory for further morphologic analysis to determine the species.”

It should correctly state “The formalin-preserved nematode sample collected in Monterey was sent to the Monterey County Public Health laboratory, where it was identified morphologically as *Thelazia* spp. The sample was then forwarded to the Centers for Disease Control and Prevention (CDC) Parasitic Diseases Reference Laboratory for further morphologic analysis to determine the species.”

The author regrets this error.

DOI: 10.1093/cid/ciz1128